Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Unicycive Therapeutics Inc
(NQ:
UNCY
)
0.5300
+0.0022 (+0.42%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Unicycive Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Friday's Intraday Session
March 10, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
March 10, 2023
Via
Benzinga
Why Barnes & Noble Education Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
March 10, 2023
Gainers Barnes & Noble Education, Inc. (NYSE: BNED) rose 25% to $2.15 in pre-market trading after the company posted better-than-expected quarterly sales.
Via
Benzinga
Why JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 09, 2023
Gainers
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
March 09, 2023
Via
Benzinga
BioMedNewsBreaks – Unicycive Therapeutics Inc. (NASDAQ: UNCY) Announces up to $130M to Commercialize and Launch Investigational New Drug
March 08, 2023
Via
Investor Brand Network
Looking Into Unicycive Therapeutics's Recent Short Interest
March 08, 2023
Via
Benzinga
Unicycive: The Company Developing Key Kidney Therapies
February 17, 2023
by\nJohnny Rice, Benzinga Contributor
Via
News Direct
Unicycive: The Company Developing Key Kidney Therapies
February 17, 2023
Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga.
Via
TheNewswire.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 08, 2023
Via
Benzinga
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 07, 2023
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 07, 2023
Via
Benzinga
Dow Tumbles 250 Points Following Powell's Comments; Crude Oil Down 2%
March 07, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 250 points on Tuesday. The Dow traded down 0.77% to 33,172.39 while the NASDAQ fell 0.72% to 11,591.36. The S&P 500...
Via
Benzinga
The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
March 07, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
March 07, 2023
The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
Via
News Direct
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 07, 2023
Via
Benzinga
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
March 06, 2023
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P...
Via
Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 06, 2023
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 06, 2023
Via
Benzinga
Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher
March 06, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500...
Via
Benzinga
Why Unicycive Therapeutics Stock Is Exploding Higher Monday
March 06, 2023
Unicycive Therapeutics Inc (NASDAQ: UNCY) shares are exploding higher Monday after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 06, 2023
Via
Benzinga
The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
March 06, 2023
Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company spearheading efforts to develop effective, safe, and novel treatments for kidney disease to improve patient and caregiver...
Via
Benzinga
Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome
March 06, 2023
Via
Benzinga
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
March 06, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
March 03, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
March 03, 2023
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
Via
News Direct
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
March 02, 2023
Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company committed to developing effective and safe treatments for kidney (renal) disease to reduce death rates and improve patients and...
Via
Benzinga
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
February 27, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive: The Company Developing Key Kidney Therapies
February 16, 2023
Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.